Overview

Modified Bortezomib-based Combination Therapy for Multiple Myeloma

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy of a modified bortezomib based combination therapy for patients with multiple myeloma.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Treatments:
BB 1101
Bortezomib
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Liposomal doxorubicin
Thalidomide